Repare Therapeutics Inc. (RPTX) financial statements (2022 and earlier)

Company profile

Business Address 7210 FREDERICK-BANTING, SUITE 100
ST-LAURENT, QC H4S 2A1
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments341,866333,710
Cash and cash equivalents334,427326,184
Short-term investments7,4397,526
Prepaid expense6,3146,678
Other undisclosed current assets3,2346,164
Total current assets:351,414346,552
Noncurrent Assets
Operating lease, right-of-use asset7,4914,674
Property, plant and equipment5,6043,948
Restricted cash and investments 212
Deferred income tax assets3,6201,412
Other noncurrent assets586288
Total noncurrent assets:17,30110,534
TOTAL ASSETS:368,715357,086
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,0795,476
Accounts payable2,3022,251
Accrued liabilities387436
Employee-related liabilities4,8672,771
Taxes payable52318
Deferred revenue11,9212,073
Other liabilities377184
Other undisclosed current liabilities14,7123,281
Total current liabilities:35,08911,014
Noncurrent Liabilities
Long-term debt and lease obligation5,5923,308
Operating lease, liability5,5923,308
Liabilities, other than long-term debt39,61355,934
Deferred revenue39,61355,934
Total noncurrent liabilities:45,20559,242
Total liabilities:80,29470,256
Stockholders' equity
Stockholders' equity attributable to parent288,421286,830
Common stock480,699384,313
Additional paid in capital17,9885,875
Accumulated deficit(210,266)(103,358)
Total stockholders' equity:288,421286,830
TOTAL LIABILITIES AND EQUITY:368,715357,086

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Gross profit:(1,873)(890)
Operating expenses(116,260)(54,437)
Other undisclosed operating income9,4731,025
Operating loss:(108,660)(54,302)
Nonoperating income (expense)74(440)
Investment income, nonoperating259240
Foreign currency transaction loss, before tax(144)(664)
Other nonoperating expense(41)(16)
Loss from continuing operations before income taxes:(108,586)(54,742)
Income tax benefit1,6781,325
Net loss available to common stockholders, diluted:(106,908)(53,417)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(106,908)(53,417)
Comprehensive loss, net of tax, attributable to parent:(106,908)(53,417)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: